Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 9% Improvement Relative Risk ICU admission -20% Hospitalization time 12% no CI Lamback et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 193 patients in Brazil No significant difference in outcomes seen Lamback et al., The Brazilian J. Infectious Dise.., doi:10.1016/j.bjid.2021.101549 Favors HCQ Favors control
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
Lamback et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101549
Lamback et al., Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19, The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101549
Feb 2021   Source   PDF  
  All Studies   Meta
Retrospective 193 hospitalized patients in Brazil not finding a significant difference with HCQ.
The control group was composed of patients refusing HCQ or with contraindications. Time based confounding is very likely because HCQ became more controversial in Brazil over the time covered (Mar - Jun 2020), while overall treatment protocols during this period improved dramatically, i.e., more control patients (those refusing HCQ) likely come later in the period when treatment protocols were greatly improved.
The paper does not mention the word "confounding" or make any adjustments. This study is excluded in the after exclusion results of meta analysis: substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically.
risk of death, 8.9% lower, RR 0.91, p = 0.83, treatment 11 of 101 (10.9%), control 11 of 92 (12.0%), NNT 94.
risk of ICU admission, 19.9% higher, RR 1.20, p = 0.61, treatment 25 of 101 (24.8%), control 19 of 92 (20.7%).
hospitalization time, 12.5% lower, relative time 0.88, treatment 101, control 92.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lamback et al., 19 Feb 2021, retrospective, Brazil, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: braz j infect dis ( 2 0 2 1 );2 5(2):101549 The Brazilian Journal of INFECTIOUS DISEASES Original article Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 Elisa Baranski Lamback a,b,∗ , Monica Amorim de Oliveira a,c , Andrea Ferreira Haddad a , André Filipe Marcondes Vieira a,c,d , Armando Leão Ferreira Neto a,e , Taciana da Silva Maia e , Juliana de Rezende Chrisman f , Pedro Pimenta de Mello Spineti a,e , Marco Antonio de Mattos a , Eduardo Costa e,f a Hospital Unimed Rio, Rio de Janeiro, RJ, Brazil Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, RJ, Brazil c Universidade Estácio de Sá, Rio de Janeiro, RJ, Brazil d Universidade Federal Fluminense, Niterói, RJ, Brazil e Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil f Instituto Unimed-Rio, Rio de Janeiro, RJ, Brazil b a r t i c l e i n f o a b s t r a c t Article history: Objectives: To assess the efficacy of hydroxychloroquine in combination with azithromycin Received 6 November 2020 in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized Accepted 4 February 2021 for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse Available online 19 February 2021 events. Keywords: Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 Method: Retrospective comparative study, based in a quaternary private hospital in Rio de COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes. Severe acute respiratory syndrome Results: The active group comprised 101 (52.3%) patients using hydroxychloroquine associ- coronavirus 2 ated with azithromycin and the control group 92 (47.7%) patients who did not take these Hydroxychloroquine medications. Median age was 59 (47–70) in the active group and 65 (47−77) in the control Azithromycin group (p < 0.05). Patients in the control group had greater extent of pulmonary involvement on baseline chest CT scans (p < 0.05). All other baseline variables (BMI, comorbidities, previous use of medications and biochemical assessments) were similar between groups. In the medication group, 25% (25 out of 101) were admitted to the ICU, compared to 21% (19 out of 92) in the control group (p > 0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation. Conclusions: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ∗ Corresponding author at: Hospital Unimed Rio, Rio de Janeiro, RJ, Brazil. E-mail address: (E.B. Lamback). 1413-8670/© 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license ( 2 b r a z j i n f e c t d i s . ( 2 0 2 1 );2 5(2):101549 ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events. © 2021 Sociedade Brasileira de Infectologia. Published by Elsevier..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop